Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective of the single-rising dose (SRD) part (trial part 1) is to investigate the safety and tolerability of BI 730460 in healthy subjects following oral administration of single rising doses. The secondary objective is the exploration of the pharmacokinetics (PK) including dose proportionality, and pharmacodynamics of BI 730460 after single dosing.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
In addition, the following trial-specific exclusion criteria apply:
Primary purpose
Allocation
Interventional model
Masking
48 participants in 7 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal